Effect of Grape Polyphenols on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials

Shao-Hua Li*, Peng Zhao, Hong-Bo Tian, Liang-Hua Chen, Lian-Qun Cui
Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

* lishaohua82@gmail.com

Abstract

Background
The effect of grape polyphenols on blood pressure remains unclear, which we aimed to address via a meta-analysis study.

Methods
We conducted study trial searches in PubMed, Embase, and the Cochrane Library databases. Summary estimates of weighted mean differences and 95% confidence intervals were obtained by using fixed-effects models. Subgroup analyses were performed to identify the source of heterogeneity. The protocol details of our meta-analysis have been submitted to the international database of prospectively registered systematic reviews (registration number CRD42015019196).

Results
Ten studies were included in the present meta-analysis. Our results showed daily grape polyphenol intake could significantly reduce systolic blood pressure by 1.48 mmHg when compared to control subjects (12 comparisons; -1.48 [-2.79 to -0.16] mmHg; \(P = 0.03\)). Subgroup analyses indicated larger reduction was identified in the intake of low-dose of grape polyphenols (< 733 mg/day, median level of the included studies) or patients with metabolic syndrome. Contrarily, diastolic blood pressure was not significantly decreased in the grape polyphenols group as compared to controls. No significant heterogeneity or publication bias was detected in the meta-analysis of either systolic or diastolic blood pressure.

Conclusions
Daily grape polyphenol intake can significantly reduce the systolic blood pressure in humans, although the reduction is modest when compared with anti-hypertensive medications. Larger, better designed trials, that specifically include hypertensive subjects, are required to verify our results in the future.
Introduction

Blood pressure is a pivotal parameter of the cardiovascular system, and hypertension is an important risk factor for cardiovascular diseases [1]. A previous study revealed that a 4-5mmHg reduction in systolic blood pressure and a 2-3mmHg reduction in diastolic blood pressure could significantly reduce cardiovascular risk by 8%-20% [2]. In addition to anti-hypertensive medications, improvement of blood pressure by dietary interventions has been recommended by the American Heart Association [3].

Grape products contain polyphenols, such as anthocyanins, flavanols and flavonols, as well as phenolic acids [4]. Experimental studies have indicated that these polyphenols may increase nitric oxide (NO) bioavailability, improve insulin sensitivity, antioxidant protection, and decrease blood viscosity [5-7]. In vivo animal studies have further demonstrated that grape polyphenols can induce an endothelium-dependent relaxation in rabbits, [8] and reduce arterial blood pressure in hypertensive rats [9]. However, the precise effect of grape polyphenols on blood pressure in humans has not been well clarified. Some studies reported that daily oral grape polyphenol intake could significantly decrease systolic or diastolic blood pressure [10-14]; whereas others showed that blood pressure might be not changed, and even increased, after daily grape polyphenol supplementation [15-19].

Feringa et al. included 5 trials (until 2010) and conducted a meta-analysis investigating the effect of grape polyphenols on blood pressure [20]. However, one important trial published in 2008 [10] was not included in Feringa’s meta-analysis, and significant publication bias could be found in the analysis of diastolic blood pressure. Furthermore, many new clinical trials have been published since 2010 [12,14,17,19]. Therefore, a new meta-analysis is necessary to explore the precise effects of grape polyphenols on blood pressure in humans. In the present study, we identified all published, randomized, and controlled trials of grape polyphenols and performed a meta-analysis to evaluate the effect of grape polyphenols on systolic and diastolic blood pressure in human subjects.

Materials and Methods

The present meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [21]. The protocol details and the PRISMA checklist have been provided in S1 and S2 Tables. Meanwhile, the protocol details of our present meta-analysis have been submitted to the PROSPERO register and this record has been published on the database at http://www.crd.york.ac.uk/prospero/. Our registration number is CRD42015019196.

Search strategy and selection criteria

According to PRISMA guidelines, we systematically searched PubMed (from 1950 to March, 2015), EMBASE (from 1966 to March, 2015), and the Cochrane Library for published reports by using the query “(grape) OR (polyphenol)” paired with “(blood pressure) OR (hypertension).” In addition, a manual search of references from reports of clinical trials or review articles was performed to identify relevant trials. When applicable, attempts were also made to contact investigators for clarification or additional unpublished data.

Studies were selected for analysis if they met the following criteria: (i) the article was published in English; (ii) study was a randomized and controlled trial in humans; (iii) the subjects in the trial were exposed to the intervention for a minimum of 2 weeks; (iv) means of systolic blood pressure and diastolic blood pressure at the beginning and end of the intervention or the differences of systolic blood pressure and diastolic blood pressure between the beginning and end of the intervention were reported; (v) the dose of grape polyphenols was provided.
Data extraction and quality assessment

According to the predefined inclusion criteria, two reviewers (Shao-Hua Li and Peng Zhao) independently completed the search, data extraction, and quality assessment. Any discrepancies between the two reviewers were resolved through discussion until a consensus was reached. The extracted data included the study characteristics (authors, publication year, sample size, study design), population information (mean age, body mass index, healthy status), the dose of grape polyphenols supplementation, the duration of the intervention, and the systolic and diastolic blood pressure at the start and end of the intervention. If alcoholized and de-alcoholized red wine were both used as the supplementation of grape polyphenols, only the de-alcoholized data were extracted because the alcohol may also affect the blood pressure [22,23]. Meanwhile, if trial conducted two different doses of grape polyphenols (low-dose and high-dose) as the intervention, both the low-dose and high-dose data were extracted and separated into two independent trials (low-dose trial and high-dose trial).

The quality of the studies was judged by the following criteria: 1) randomization; 2) concealment of treatment allocation; 3) participant masking; 4) researcher masking; 5) reporting of withdrawals; 6) generation of random numbers; and 7) reporting of industry funding. Trials scored one point for each area addressed in the study design (randomization, blinding, concealment of allocation, reporting of withdrawals, and generation of random numbers), with a possible score of between 0 and 5 [24] (highest level of quality).

Statistical analysis

The primary outcome was the overall changes of systolic and diastolic blood pressure between the beginning and the end of the intervention. If the changes in systolic and diastolic blood pressure were not reported in the study, we calculated them according to the Cochrane Handbook for Systematic Review and Follman D’s theory for overview of clinical trials with continuous variables [25]. We assumed equal variance among trials and between intervention and controls. Weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated for net changes in systolic and diastolic blood pressure by using fixed-effect models [26]. Statistic heterogeneity of treatment effects between studies was formally tested with Cochran’s test \( (P < 0.1) \). The \( I^2 \) statistic was also examined, and we considered an \( I^2 \) value >50% to indicate significant heterogeneity between the trials [27]. Furthermore, subgroup analyses were also performed to identify the possible sources of heterogeneity by comparing summary results obtained from subsets of studies grouped by age, body mass index, duration of intervention, health status of the subjects and the dose of grape polyphenols. Publication bias was assessed with the Egger regression test and Begg’s funnel plots [28]. Meta-analysis and statistical analyses were performed with Stata software (version 10.0; Stata Corporation, College Station, TX, USA) and REVMAN software (version 5.0; Cochrane Collaboration, Oxford, UK).

Results

Search results

The flow chart of identification process is presented in Fig 1. A total of 572 articles were initially identified in a combined search of the PubMed, EMBASE, and Cochrane Library databases, of which 548 were excluded because they were studied in animals or in vitro, or because the objectives were not related to the present meta-analysis. The remaining 24 potentially relevant articles were examined for full text evaluation [10–19,22,29–41]. Of the 24 studies, 10 eligible randomized controlled trials were included in the present meta-analysis [10–19]. The other 14 articles were excluded for the following reasons: five studies were not randomized...
Fig 1. Identification process for eligible studies. Articles were initially identified in a combined search from PubMed, EMBASE, and Cochrane Library databases.

doi:10.1371/journal.pone.0137665.g001
controlled design \cite{29,31,32,35,36}; blood pressure was not measured in 4 trials \cite{33,34,37,39}; the exact values of systolic and diastolic blood pressure at the start and end of the intervention or the change of systolic and diastolic blood pressure between the start and end of the intervention were not reported or calculated in five studies \cite{22,30,38,40,41}, but Hodgson et al \cite{40} actually reported data in another article \cite{15} which has been included in our present meta-analysis.

**Study characteristics**

The characteristics of the 10 studies are presented in Table 1. All the 10 trials were randomized controlled, and 8 were double-blind design \cite{11–15,17–19}. Of the 10 trials, 5 studies included healthy adults \cite{10,12,16,18,19}, and others enrolled hypertensive patients \cite{15}, subjects with high vascular risk \cite{13}, or metabolic syndrome \cite{11,14}, or patients with coronary disease \cite{17}. The sample size of the 10 trials ranged from 9 to 70. The average age of the subjects ranged from 31.4 to 63.7 years old, and the body mass index varied from 23.2 kg/m\(^2\) to 36 kg/m\(^2\). Doses of grape polyphenols in these trials ranged from 150 mg/d to 1400 mg/d. The duration of treatment ranged from 2 weeks to 16 weeks.

Two studies \cite{11,16} used two different doses of grape polyphenols (low-dose and high-dose) as the interventions, so the low-dose and high-dose groups were separated into two independent trials in the present meta-analysis. Queipo-Ortuno’s trial \cite{12} designed an alcoholized and a de-alcoholized group to investigate the effect of grape polyphenols on blood pressure, and we only extracted the de-alcoholized data to our present meta-analysis because the alcohol could likely affect blood pressure \cite{22,23}. The baseline and final values of systolic and diastolic blood pressure for the included trials are shown in Table 1.

The quality score of the 10 studies ranged from 1 to 4. Eight were randomized, double-blinded controlled studies \cite{11–15,17–19}, and one was single-blinded trial \cite{16}. Six of the 10 studies reported the details of withdrawals \cite{12,13,15,16,18,19}, whereas the other four studies did not address this issue \cite{10,11,14,17}.

**The effect of grape polyphenols on blood pressure**

Of the 10 trials, five showed a significant reduction in systolic blood pressure \cite{10–14}, other trials reported no significant difference in systolic blood pressure after grape polyphenols intervention \cite{15–19}. The data of systolic blood pressure were extracted and pooled from the included studies, and the present meta-analysis showed that a significant reduction in systolic blood pressure by 1.48mmHg in the grape polyphenols-supplemented subjects than in control subjects (12 comparisons; WMD: -1.48mmHg; 95\% CI: -2.79 to -0.16mmHg; \(P = 0.03\)) (Fig 2). No significant heterogeneity could be detected in the meta-analysis of systolic blood pressure (heterogeneity \(I^2 = 32\%, P = 0.14\)). Subgroup analyses were performed to identify the possible sources of heterogeneity, and the results showed that systolic blood pressure was significantly reduced in low-dose of grape polyphenols (< 733 mg/day) when compared to the high-dose groups (\(P = 0.009\)). Meanwhile, the systolic blood pressure in metabolic syndrome patients (WMD: -7.05 mmHg, 95 CI: -10.97 to -3.12 mmHg) was also obviously decreased after intake of grape polyphenols when compared with other two subgroups (\(P = 0.03\)). No significant differences could be detected in other subgroup analyses (age, body mass index and duration). (S3 Table)

When estimating the diastolic blood pressure, three trials reported a significant reduction in diastolic blood pressure \cite{10–12}, and other seven trials reported no significant change of diastolic blood pressure after grape polyphenols supplementation \cite{13–19}. The present meta-analysis was conducted and the result indicated that no significant reduction in diastolic blood
Table 1. Characteristics of the included trials investigating the effects of grape polyphenols on blood pressure. R, randomized; SB, single-blind; DB, double-blind; PC, placebo-controlled; Con, controlled; CO, crossover; BMI, body mass index.

| Author                | Year | Study Design | Health status of subjects | Number of subjects | Mean age (year) | BMI (kg/m²) | Duration | Dose of grape polyphenols | Systolic blood pressure * | Diastolic blood pressure * |
|-----------------------|------|--------------|---------------------------|--------------------|----------------|-------------|----------|---------------------------|---------------------------|---------------------------|
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Clifton et al         | 2004 | R DB CO      | High vascular risk        | Grape: 35 Control: 35 | 58             | 28.4        | 4 weeks  | 1000 mg/day               | 127±15 / 124±14          | 127±15 / 124±13           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Ward et al            | 2005 | R DB PC      | Hypertensive patients     | Grape: 16 Control: 18 | 62.5           | 28.5        | 6 weeks  | 1000 mg/day               | 133.6±11.6 / Not reported | 134.1±8.2 / Not reported   |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Sano et al 200mg      | 2007 | R SB PC      | Healthy subjects          | Grape: 18 Control: 18 | 52             | 24.2        | 12 weeks | 200 mg/day                | 126.4±12.6 / 129.2±13.66  | 122.7±18.6 / 127.8±20.53   |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Sano et al 400mg      | 2007 | R SB PC      | Healthy subjects          | Grape: 18 Control: 17 | 52             | 24.2        | 12 weeks | 400 mg/day                | 126.2±16.4 / 127.7±12.37  | 121.5±14.0 / 113.7±9.4     |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Jimenez et al         | 2008 | R Con        | Non-smokers               | Grape: 34 Control: 9 | 35.3           | 25.4        | 16 weeks | 1400 mg/day               | 126.5±22.1 / 118±19.6     | 127.8±20.5 / 113±9.4       |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Sivaprakasapillai et al 2009 | R DB PC | Metabolic syndrome | Grape: 9 Control: 9 | 46             | 36           | 4 weeks  | 150 mg/day               | 134±15 / 123±12           | 123±12 / 121±12           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Sivaprakasapillai et al 2009 | R DB PC | Metabolic syndrome | Grape: 9 Control: 9 | 46             | 36           | 4 weeks  | 300 mg/day               | 127±12 / 116±9            | 123±12 / 121±12           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Mellen et al          | 2010 | R DB PC CO   | Coronary disease          | Grape: 50 Control: 50 | 52.1           | 28.2        | 4 weeks  | 1300 mg/day               | 122.4±11.3 / 125.2±14.14   | 124.6±12.73 / 123.2±14.14  |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| van Mierlo et al      | 2010 | R DB PC CO   | Healthy males             | Grape: 35 Control: 35 | 31.4           | 23.2        | 2 weeks  | 800 mg/day                | 123±10.5 / 118±10.4       | 123±10.5 / 118±7.1        |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Barona et al          | 2012 | R DB CO      | Metabolic syndrome        | Grape: 24 Control: 24 | 51.3           | 31.5        | 30 days  | 267 mg/day                | 131±10 / 122±11           | 131±10 / 126±10           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Queipo-ortuno et al   | 2012 | R DB CO      | Healthy males             | Grape: 10 Control: 10 | 48             | 27.6        | 20 days  | 733 mg/day                | 145.4±23.9 / 135.1±24.6   | 145.4±23.9 / 142.7±22.3   |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |
| Ras et al             | 2013 | R DB PC      | Healthy subjects          | Grape: 34 Control: 35 | 63.7           | 25.5        | 8 weeks  | 300 mg/day               | 135.8±11.08 / 130.3±9.91   | 135.7±10.06 / 132.5±10.06  |
|                       |      |              |                           |                    |                |             |          |                           |                           |                           |

* Values are the Mean ± SDs reported or calculated.
pressure was observed between the grape polyphenols-supplemented subjects and controls (12 comparisons; WMD: -0.50 mmHg; 95% CI: -1.46 to 0.46 mmHg; P = 0.31) (Fig 3). Similarly, no heterogeneity could be found in the meta-analysis of diastolic blood pressure (heterogeneity $I^2 = 0\%$, $P = 0.53$). Subgroup analyses were also performed but no significant differences could be detected in the analyses based on age, body mass index, duration, health status of the subjects or the dose of grape polyphenols. (S3 Table)

**Sensitivity analysis**

Sensitivity analysis showed that the overall estimates of the changes in blood pressure were not altered after excluding the low-quality studies [10,16]. Exclusion of the low-quality studies [10,16] led to a small attenuation of the changes in blood pressure (systolic blood pressure: -1.43 [-2.79, -0.07], $P = 0.04$; diastolic blood pressure: -0.32 [-1.32, 0.67], $P = 0.52$), but the grape polyphenols intake still resulted in a significant reduction of systolic blood pressure.

**Publication bias**

The publication bias of trials was assessed by the statistical analyses of the Egger test and funnel plots [28]. No publication bias was found in the meta-analysis of systolic blood pressure (Egger test, $P = 0.234$) and diastolic blood pressure (Egger test, $P = 0.119$).
Discussion

The present meta-analysis showed that daily intake of grape polyphenols could significantly reduce systolic blood pressure by 1.48 mmHg when compared with control subjects. No significant heterogeneity publication bias could be detected in the meta-analysis of systolic blood pressure. Subgroup analysis indicated that larger reduction was identified in the intake of low-dose of grape polyphenols (< 733 mg/day, median level of the included studies) or patients with metabolic syndrome. In contrast, diastolic blood pressure was not significantly decreased in the grape polyphenols intervention group as compared with controls, and no significant heterogeneity or publication bias was found in the meta-analysis of diastolic blood pressure. Therefore, the present study supported the hypothesis that daily grape polyphenol intake might affect systolic blood pressure, but not diastolic blood pressure.

Significant increases of NO could be detected in human umbilical vein endothelial cells after being treated with grape polyphenol extract in vitro [42]. In vivo animal studies have further demonstrated that grape polyphenols induce an endothelium-dependent relaxation in rabbits, [8] and reduce arterial blood pressure in hypertensive rats [9], but the precise effects of grape polyphenols on blood pressure in humans has not been established. Feringa et al included 5 trials (until 2010) and conducted a meta-analysis investigating the effect of grape polyphenols on blood pressure [20], but one important trial published in 2008 [10] was not included in
Feringa's meta-analysis, and the significant publication bias cloud be found in the meta-analysis of diastolic blood pressure. Moreover, some new trials investigating the effect of grape polyphenols on blood pressure have been published since 2010 [12,14,17,19], thus a new meta-analysis is needed to further explore the precise effect of grape polyphenols on systolic and diastolic blood pressure in humans. The present meta-analysis revealed that grape polyphenols intake resulted in a significant reduction of systolic blood pressure, but had no effect on diastolic blood pressure. The mean decrease of 1.48mmHg for systolic blood pressure was modest when compared with antihypertensive medications, but previous study revealed that a 4-5mmHg reduction in systolic blood pressure might significantly reduce cardiovascular risk by 8%-20% [2].

The precise mechanisms of grape polyphenols in reducing blood pressure are currently unknown. The majority of studies suggested that the stimulation and promotion of the release of NO, resulting in the vasorelaxation, might be the main cause of hypotensive effect of grape polyphenols. Peng et al. found that the arterial blood pressure in hypertensive rats was significantly decreased after the supplementation of grape seed extract for 4 weeks [43]. Barona et al. further demonstrated that there was a negative association between the reduction of systolic blood pressure and the increased production of NO in patients with metabolic syndrome [14]. Our present meta-analysis included 10 randomized controlled trials and conducted a new meta-analysis, and the results showed that grape polyphenols intake in the daily life could significantly reduce the systolic blood pressure, but not diastolic blood pressure, consistent with the conclusions of Barona's study [14] and previous Feringa's meta-analysis [20]. Furthermore, our subgroup analyses showed that low-dose of grape polyphenols supplementation might lead to a significant reduction of systolic blood pressure. Edirisinghe et al. demonstrated that 1.0 μmol/L grape seed extracts could induce the most significant relaxation of rabbit aortic rings in vitro, but no further prominent change of rabbit aortic rings could be found at higher concentrations (10μmol/L or 100μmol/L) of grape seed extracts [8], which might partially explain the results of our subgroup analysis. Meanwhile, our subgroup analysis also indicated that the systolic blood pressure in patients with metabolic syndrome was obviously decreased after intake of grape polyphenols, which might be ascribed to the impaired endothelial function in metabolic syndrome. Our previous meta-analysis [44] and other studies [38,45] showed that intake of grape polyphenols could significantly improve the endothelial function, especially subjects with high cardiovascular risk factors. However, the exact mechanisms of grape polyphenols on blood pressure are still unclear and need to be further explored in the future.

Despite the interesting results of the present meta-analysis, several potential limitations should be addressed. First, the sample sizes in the included trials, which varied from 10 to 50 subjects, were still small; therefore, larger and better designed trials are needed to verify our conclusions in the future. Secondly, hypertensive patients enrolled in the present meta-analysis was limited; only one trial [15] included hypertensive subjects and other two trials enrolled patients with metabolic syndrome [11,14]. Whether the effect of grape polyphenols on blood pressure might be more significant in hypertensive subjects, especially in patients with severe hypertension, are needed to be confirmed in the future. Thirdly, lifestyle modifications during the intervention of grape polyphenols were not reported in majority of the included studies. The effect of grape polyphenols on blood pressure might be influenced by different lifestyle modifications and diets. Fourthly, although our subgroup analyses showed the low-dose of grape polyphenols supplementation might lead to a more significant reduction of systolic blood pressure, the doses of included trials varied from 150mg/day to 1400mg/day; therefore, more trials using other doses of grape polyphenols supplementation are needed to verify our present results. Fifth, although the mean reduction of 1.48 mmHg for systolic blood pressure was statistically significant, the biological action generated from the effect of grape polyphenols
Grape Polyphenols on Blood Pressure

has been not well clarified, might be less important than antihypertensive drugs, because some antihypertensive drugs have a well-established biological action on target organ damage irrespective of the antihypertensive effect. Therefore, the biological action of grape polyphenols should be well clarified in the future.

Conclusively, our present meta-analysis indicates that daily intake of grape polyphenols can significantly reduce systolic blood pressure in humans, although the reduction is modest when compared with antihypertensive medications. Larger, better designed studies that also include hypertensive subjects are required to verify our present results.

Supporting Information

S1 Table. The protocol of the present meta-analysis. This is the detailed protocol of the present meta-analysis.

(SDOC)

S2 Table. The PRISMA 2009 checklist of the present meta-analysis. This is the detailed checklist of the present meta-analysis according to the PRISMA guideline.

(SDOC)

S3 Table. Subgroup analyses for the effect of grape polyphenols on blood pressure. The subgroup analyses were performed and showed as supporting information.

(SDOC)

Acknowledgments

We thank LetPub for its linguistic assistance during the preparation of this manuscript.

Author Contributions

Conceived and designed the experiments: SHL LQC. Performed the experiments: SHL PZ. Analyzed the data: SHL PZ. Contributed reagents/materials/analysis tools: SHL PZ HBT LHC. Wrote the paper: SHL LQC.

References

1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507–520. doi: 10.1001/jama.2013.284427 PMID: 24352797

2. McInnes GT. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl. 2005; 23: S3–8.

3. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006; 47:296–308. PMID: 16434724

4. Xia EQ, Deng GF, Guo YJ, Li HB. Biological activities of polyphenols from grapes. Int J Mol Sci. 2010; 11:622–646. doi: 10.3390/ijms11020622 PMID: 20386657

5. Zern TL, Fernandez ML. Cardioprotective effects of dietary polyphenols. J Nutr. 2005; 135:2291–2294. PMID: 16177184

6. Vita JA. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin Nutr. 2005; 81:292S–297S. PMID: 15640493

7. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost. 2010; 36:59–70. doi: 10.1055/s-0030-1248729 PMID: 20391297

8. Edirisinghe I, Burton-Freeman B, Tissa Kappagoda C. Mechanism of the endothelium-dependent relaxation evoked by a grape seed extract. Clin Sci (Lond). 2008; 114:331–337.
9. Lopez-Sepulveda R, Jimenez R, Romero M, Zarzuelo MJ, Sanchez M, Gomez-Guzman M, et al. Wine polyphenols improve endothelial function in large vessels of female spontaneously hypertensive rats. Hypertension. 2008; 51:1088–1095. doi: 10.1161/HYPERTENSIONAHA.107.107672 PMID: 18259008

10. Jimenez JP, Serrano J, Tabenero M, Arranz S, Diaz-Rubio ME, Garcia-Diz L, et al. Effects of grape antioxidant dietary fiber in cardiovascular disease risk factors. Nutrition. 2008; 24:646–653. doi: 10.1016/j.nut.2008.03.012 PMID: 18485668

11. Sivaprakasapillai B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism. 2009; 58:1743–1746. doi: 10.1016/j.metabol.2009.05.030 PMID: 19608210

12. Queipo-Ortuno MI, Boto-Ordonez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, et al. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr. 2012; 95:1323–1334. doi: 10.3945/ajcn.111.278747 PMID: 22520277

13. Clifton PM. Effect of Grape Seed Extract and Quercetin on Cardiovascular and Endothelial Parameters in High-Risk Subjects. J Biomed Biotechnol. 2004; 2004:272–278. PMID: 15577189

14. Barona J, Aristizabal JC, Blesso CN, Volek JS, Fernandez ML. Grape polyphenols reduce blood pressure and increase flow-mediated vasodilation in men with metabolic syndrome. J Nutr. 2012; 142:1626–1632. doi: 10.3945/jn.111.126274 PMID: 22810991

15. Ward NC, Hodgson JM, Croft KD, Burke V, Belin LJ, Puddey IB. The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005; 23:427–434. PMID: 15662232

16. Sano A, Uchida R, Saito M, Shioya N, Komori Y, Tho Y, et al. Beneficial effects of grape seed extract on malondialdehyde-modified LDL. J Nutr Sci Vitaminol (Tokyo). 2007; 53:174–182.

17. Mellen PB, Daniel KR, Brosnihan KB, Hansen KJ, Herrington DM. Effect of muscadine grape seed supplementation on vascular function in subjects with or at risk for cardiovascular disease: a randomized crossover trial. J Am Coll Nutr. 2010; 29:469–475. PMID: 21504973

18. van Mierlo LA, Zock PL, van der Knap HC, Draijer R. Grape polyphenols do not affect vascular function in healthy men. J Nutr. 2010; 140:1769–1773. doi: 10.3945/jn.110.125518 PMID: 20702747

19. Ras RT, Zock PL, Zebregs YE, Johnston NR, Webb DJ, Draijer R. Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension. Br J Nutr. 2013; 110:2234–2241. doi: 10.1017/S000711451300161X PMID: 23702253

20. Feringa HH, Laskey DA, Dickson JE, Coleman CI. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. J Am Diet Assoc. 2011; 111:1173–1181. doi: 10.1016/j.jada.2011.05.015 PMID: 21802563

21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. doi: 10.1136/bmj.b2535 PMID: 19622551

22. Zilkens RR, Burke V, Hodgson JM, Barden A, Belin LJ, Puddey IB. Red wine and beer elevate blood pressure in normotensive men. Hypertension. 2005; 45:874–879. PMID: 15837829

23. Halanych JH, Safford MM, Kertesz SG, Pletcher MJ, Kim YI, Person SD, et al. Alcohol consumption in young adults and incident hypertension: 20-year follow-up from the Coronary Artery Risk Development in Young Adults Study. Am J Epidemiol. 2010; 171:532–539. doi: 10.1093/aje/kwp117 PMID: 20118194

24. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? J Clin Epidemiol. 1992; 45:769–773. PMID: 1619456

25. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1999; 52:1250–1257. PMID: 14584675
31. Park YK, Kim JS, Kang MH. Concord grape juice supplementation reduces blood pressure in Korean hypertensive men: double-blind, placebo controlled intervention trial. Biofactors. 2004; 22:145–147. PMID: 15630270

32. Zern TL, Wood RJ, Greene C, West KL, Liu Y, Aggarwal D, et al. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005; 135:1911–1917. PMID: 16046716

33. Castilla P, Echarri R, Davalos A, Cerrato F, Ortega H, Teruel JL, et al. Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr. 2006; 84:252–262. PMID: 16825703

34. Castilla P, Davalos A, Teruel JL, Cerrato F, Fernandez-Lucas M, Merino JL, et al. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr. 2008; 87:1053–1061. PMID: 18400731

35. Puglisi MJ, Vaishnav U, Shrestha S, Torres-Gonzalez M, Wood RJ, Volek JS, et al. Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines. Lipids Health Dis. 2008; 7:14. doi:10.1186/1476-511X-7-14 PMID: 18416823

36. Andrade AC, Cesena FH, Consolim-Colombo FM, Coimbra SR, Benjo AM, Krieger EM, et al. Short-term red wine consumption promotes differential effects on plasma levels of high-density lipoprotein cholesterol, sympathetic activity, and endothelial function in hypercholesterolemic, hypertensive, and healthy subjects. Clinics (Sao Paulo). 2009; 64:435–442.

37. Hollis JH, Houchins JA, Blumberg JB, Mattes RD. Effects of concord grape juice on appetite, diet, body weight, lipid profile, and antioxidant status of adults. J Am Coll Nutr. 2009; 28:574–582. PMID: 20439553

38. Magyar K, Halmosi R, Palli A, Feher G, Czopf L, Fulop A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012; 50:179–187. doi:10.3233/CH-2011-1424 PMID: 22240353

39. Yubero N, Sanz-Buenhombre M, Guadarrama A, Villanueva S, Carrion JM, Larrarte E, et al. LDL cholesterol-lowering effects of grape extract used as a dietary supplement on healthy volunteers. Int J Food Sci Nutr. 2013; 64:400–406. doi: 10.3109/09637486.2012.753040 PMID: 23249415

40. Hodgson JM, Croft KD, Woodman RJ, Puddey IB, Bondonno CP, Wu JH, et al. Effects of vitamin E, vitamin C and polyphenols on the rate of blood pressure variation: results of two randomised controlled trials. Br J Nutr. 2014; 112:1551–1561. doi:10.1017/S0007114514002542 PMID: 25234939

41. Zunino SJ, Peerson JM, Freytag TL, Breksa AP, Bonnel EL, Woodhouse LR, et al. Dietary grape powder increases IL-1beta and IL-6 production by lipopolysaccharide-activated monocytes and reduces plasma concentrations of large LDL and large LDL-cholesterol particles in obese humans. Br J Nutr. 2014; 112:369–380. doi: 10.1017/S0007114514000890 PMID: 24832727

42. Leikert JF, Rathel TR, Wohlfart P, Cheynier V, Vollmar AM, Dirsch VM. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation. 2002; 106:1614–1617. PMID: 12270851

43. Peng N, Clark JT, Prasain J, Kim H, White CR, Wyss JM. Antihypertensive and cognitive effects of grape polyphenols in estrogen-depleted, female, spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2005; 289:R771–775. PMID: 1610821

44. Li SH, Tian HB, Zhao HJ, Chen LH, Cui LQ. The acute effects of grape polyphenols supplementation on endothelial function in adults: meta-analyses of controlled trials. PLoS One. 2013; 8:e69818. doi: 10.1371/journal.pone.0069818 PMID: 23894543

45. Lekakis J, Rallidis LS, Andreadou I, Varvakou G, Kazantzoglou G, Magiatis P, et al. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005; 12:596–600. PMID: 16319551